PATENT CLAIM ANALYSIS

Application Number: 15751472
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["424", "133100"]

Abstract:
Methods of developing genetically engineered immune cells for immunotherapy, which can be endowed with Chimeric Antigen Receptors targeting an antigen marker that is common to both the pathological cells and said CD38 immune by the fact that the genes encoding said markers are inactivated in said immune cells by a rare cutting endonuclease such as TALEN, Cas9 or argonaute.

Claim (Index 18):
A method of preparing immune cells, preferably T-cells, for immunotherapy against pathological cells comprising the step of:\n (a) Genetically inactivating or mutating a gene encoding the CD38 gene in an immune cell, which is involved in the expression or presentation of the CD38 antigen marker, said CD38 antigen marker being present both on the surface of said immune cell and the pathological cell; (b) Expressing into said immune cell a transgene encoding a chimeric antigen receptor directed against said CD38 antigen marker according to  claim 1 , said antigen marker being present at the surface of said pathological cell.

Metadata:
- Claim Count in Document: 4.0
- Percentile: 88.0
- Lexical Diversity: 1.21569
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15302450', '15126540', '14952448', '15301686', '14403937']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7324470891888355
- 35 USC 102 Novelty (BERT): 0.5487654360017193
- Combined Prediction Score: 0.7140789238701238
- Mean Citation Score: 368.64456000000007
- Max Citation Score: 405.39853
- Similarity Product: 290.46274852965354

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test